Roivant Sciences ROIV Cash Flow Statement
| Q4 '25 | Q3 '25 | Q2 '25 | Q1 '25 | Q4 '24 | ||
|---|---|---|---|---|---|---|
| —— | -$313.7M-88.9% | -$166.04M+25.7% | -$223.36M+11.5% | -$252.38M-314% | ||
| $638K-7.7% | $691K-25.0% | $921K-16.1% | $1.1M-22.9% | $1.43M-51.2% | ||
| $77.17M-26.5% | $105M+28.3% | $81.82M-0.4% | $82.18M-1.6% | $83.49M-0.2% | ||
| $16.16M+505% | -$3.99M-233% | $3M+126% | -$11.75M-7,018% | -$165K— | ||
| $63.23M— | —— | —— | -$25M— | —— | ||
| $1.85M0.0% | $1.85M0.0% | $1.85M0.0% | $1.85M-15.3% | $2.19M0.0% | ||
| -$252K0.0% | -$252K0.0% | -$252K0.0% | -$252K-230% | $193.25K0.0% | ||
| —— | -$8.3M-359% | $3.21M+4,414% | $71K+100% | -$18.4M-388% | ||
| $21.26M0.0% | $21.26M0.0% | $21.26M0.0% | $21.26M+946% | -$2.51M0.0% | ||
| —— | $21.59M-83.2% | $128.5M+772% | -$19.13M-248% | $12.9M+161% | ||
| $1.86M-26.2% | $2.53M+30.1% | $1.94M-0.1% | $1.94M-1.5% | $1.97M+15.3% | ||
| $0— | —— | —— | —— | -$2.21M0.0% | ||
| -$275K+65.0% | -$786K+7.1% | -$846K-77.0% | -$478K-98.3% | -$241K+88.0% | ||
| -$18.45M-775% | $2.73M-37.7% | $4.39M+3,530% | -$128K— | —— | ||
| -$163.82M+16.6% | -$196.48M-5.8% | -$185.66M+9.2% | -$204.38M-18.4% | -$172.57M+16.7% | ||
| $1.26M— | —— | $7.85M+94.5% | $4.04M+398% | $811K-55.6% | ||
| $0— | $0— | —— | —— | $75M-0.3% | ||
| $629.5K0.0% | $629.5K0.0% | $629.5K0.0% | $629.5K+897% | -$79K— | ||
| $0— | $0— | $0— | $0-100% | $1.02B0.0% | ||
| —— | —— | —— | -$1.09B— | —— | ||
| —— | —— | —— | $208.29M-29.5% | $295.45M+21.4% | ||
| -$217.17M-283% | $118.81M+74.0% | $68.29M+127% | $30.06M— | $0— | ||
| $0— | $0— | $0— | $0— | $0-100% | ||
| —— | $328.19M— | —— | -$187.77M-6.0% | -$177.15M+35.1% | ||
| $1.32M+206% | $430K-64.3% | $1.21M+48.0% | $815K— | —— | ||
| -$57.79M— | —— | -$1.45M+99.9% | -$1.48B— | —— | ||
| $0— | $0— | $0— | $0-100% | $1.49M0.0% | ||
| —— | $8.72M-11.2% | $9.82M-11.2% | $11.06M-29.3% | $15.66M-46.5% | ||
| $0+100% | -$24.42M-16.5% | -$20.96M-800% | -$2.33M-116% | $14.12M— | ||
| —— | $21.59M-83.2% | $128.5M+772% | -$19.13M-248% | $12.9M+161% | ||
| $0— | $0— | $0— | $0— | $0— | ||
| $0— | —— | —— | —— | $94.13M0.0% | ||
| $16.16M+505% | -$3.99M-233% | $3M+126% | -$11.75M-7,018% | -$165K— | ||
| $0— | $0— | $0— | $0— | $0— | ||
| $192.56M0.0% | $192.56M0.0% | $192.56M0.0% | $192.56M— | $0— | ||
| -$275K+65.0% | -$786K+7.1% | -$846K-77.0% | -$478K-98.3% | -$241K+88.0% | ||
| -$18.45M-775% | $2.73M-37.7% | $4.39M+3,530% | -$128K— | —— | ||
| $3.9M0.0% | $3.9M0.0% | $3.9M0.0% | $3.9M— | $0— | ||
| $1.86M-26.2% | $2.53M+30.1% | $1.94M-0.1% | $1.94M-1.5% | $1.97M+15.3% | ||
| —— | —— | -$5.98M+46.0% | -$11.08M-162% | -$4.23M+64.5% | ||
| $4.42M— | —— | —— | —— | $74K-99.8% | ||
| $629.5K0.0% | $629.5K0.0% | $629.5K0.0% | $629.5K+897% | -$79K— | ||
| $0— | $0— | $0— | $0-100% | $1.02B0.0% | ||
| $280.58M0.0% | $280.58M0.0% | $280.58M0.0% | $280.58M— | $0— | ||
| $0— | —— | —— | —— | $27.6M0.0% | ||
| $0— | $0— | $0— | $0— | $0-100% | ||
| $8.75M-63.3% | $23.86M+268% | $6.48M-32.0% | $9.53M+27.8% | $7.46M-13.5% | ||
| $48.4M0.0% | $48.4M0.0% | $48.4M0.0% | $48.4M-57.1% | $112.78M— | ||
| —— | $39.25M— | —— | —— | $0— | ||
| $0— | $0— | —— | —— | $75M-0.3% | ||
| —— | $381K— | —— | —— | $380K— | ||
| $0— | $0— | $0— | $0— | $0-100% | ||
| $0— | $0— | $0— | $0-100% | $23.29M— | ||
| —— | —— | -$14.82M-33,775% | $44K— | —— | ||
| -$464K— | —— | —— | —— | -$98K— | ||
| $14.42M0.0% | $14.42M0.0% | $14.42M0.0% | $14.42M— | $0— | ||
| $7.78M0.0% | $7.78M0.0% | $7.78M0.0% | $7.78M— | $0— | ||
| -$165.08M+13.8% | -$191.55M+1.0% | -$193.51M+7.2% | -$208.42M-20.2% | -$173.38M+17.1% | ||
| -$165.08M+13.8% | -$191.55M+1.0% | -$193.51M+7.2% | -$208.42M-20.2% | -$173.38M+17.1% |
Chart any of these lines over time, or line them up against competitors.
Compare these in charts →Questions, answered.
- How much cash does Roivant Sciences generate?
- Roivant Sciences (ROIV) generated -$750.3M in operating cash flow over the trailing twelve months.
- What is Roivant Sciences's free cash flow?
- After $14.0M of capital expenditures, Roivant Sciences's free cash flow was -$758.6M over the trailing twelve months, up 10.1% year over year.
- Where does Roivant Sciences's cash flow data come from?
- Every line is extracted from Roivant Sciences's SEC filings (10-K and 10-Q) and tagged in XBRL. Switch between quarterly, annual, and trailing-twelve-month views, or open any line for its full history and peer comparisons.
